HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

509.662

+21.0214.30%

Number of Gainers:44

Number of Losers:8

Number of Flat:3

PE:- -

High:511.922

Open:493.898

Low:493.493

Close:488.641

Loading ...

Chinese Regulator Accepts Second BLA for Anti-Inflammatory Drug Licensed by Hansoh Pharmaceutical

MT Newswires Live

Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%

MT Newswires Live

BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio

Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio

THOMSON REUTERS

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

MT Newswires Live

BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPA

Hansoh Pharmaceutical - Second Biologics License Application of Xinyue Accepted by Nmpa

THOMSON REUTERS

China Tower Corporation Limited's (HKG:788) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Simply Wall St.

Greater China Stocks Close Mixed; Hong Kong Leads Gainers

BeiGene's Q4'24 Loss Narrows

MT Newswires Live

Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week

Simply Wall St.

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement

Simply Wall St.

Here's Why Anhui Conch Cement (HKG:914) Can Manage Its Debt Responsibly

Simply Wall St.

Recent 16% decline may not have gone down well with Ming Yuan Cloud Group Holdings Limited (HKG:909) insiders who've been purchasing recently

Simply Wall St.

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) in Melanoma

THOMSON REUTERS

Junshi Biosciences' 2024 Loss Narrows

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":509.66202,"timestamp":1741162099081,"preClose":488.6409,"halted":0,"volume":639103754,"delay":0,"changeRate":0.04302,"change":21.021118,"pbRate":2.400119,"amount":14348469744.5,"amplitude":0.037714,"prevYearClose":446.93042,"fiveDayClose":514.521,"twentyDayClose":452.099,"turnoverRate":0.004746,"marketCap":2618218524288,"floatMarketCap":2189326024832,"peRate":33.321806},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":511.9219,"amplitude":0.037714,"preClose":488.6409,"low":493.4934,"pbRate":"2.400119","latestPrice":509.66202,"volume":639103754,"delay":0,"open":493.89767,"prevYearClose":446.93042,"prevWeekClose":492.906,"prevMonthClose":492.906,"prevQuarterClose":446.93,"fiveDayClose":514.521,"twentyDayClose":452.099,"sixtyDayClose":478.022,"secType":"PLATE","market":"HK","turnoverRate":0.004746,"peRate":33.321806,"marketCap":2618218524288,"floatMarketCap":2189326024832,"timestamp":1741162099081,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":44,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517648029","title":"Chinese Regulator Accepts Second BLA for Anti-Inflammatory Drug Licensed by Hansoh Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=2517648029","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517648029?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:54","pubTimestamp":1741161265,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group  said the second biologics license application or BLA of its antibody drug XINYUE  was accepted by the National Medical Products Administration or NMPA, a Tuesday bourse filing said.The drug is a targeted CD19 B cell-depleting antibody and is used to treat immunoglobulin G4-related disease, a chronic inflammatory condition.In May 2019, Viela Bio granted the group the exclusive license to develop and commercialize the drug in China, Hong Kong, and Macau.NMPA approved the launch of the drug in China in 2022, while the drug was also included in the national reimbursement drug list in 2023, a status that was renewed in November 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1191","BK1589","03692"],"gpt_icon":0},{"id":"2517697559","title":"Indonesian Regulator Approves NDA for Antengene's White Blood Cell Anti-Cancer Drug, Shares Up 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517697559","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517697559?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:39","pubTimestamp":1741160361,"startTime":"0","endTime":"0","summary":"Antengene  obtained new drug application approval for three indications of XPOVIO  from the Indonesia National Agency of Drug and Food Control, a Wednesday Hong Kong bourse filing said.The indications include a combination with bortezomib and dexamethasone used for the treatment of multiple myeloma in adult patients, a combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma, and as a monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients.Multiple myeloma is a cancer related to the white blood cells called plasma cells, while diffuse large B-cell lymphoma is cancer related to the white blood cells called lymphocytes.Shares of the company were up nearly 11% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","06996","BK1583","BK1191"],"gpt_icon":0},{"id":"2517969313","title":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517969313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517969313?lang=en_us&edition=fundamental","pubTime":"2025-03-05 15:28","pubTimestamp":1741159699,"startTime":"0","endTime":"0","summary":"BRIEF-Antengene Gets Approval Of NDA By Indonesia National Agency Of Drug And Food Control For XpovioMarch 5  - Antengene Corp Ltd 6996.HK:APPROVAL OF NDA BY INDONESIA NATIONAL AGENCY OF DRUG AND FOOD CONTROL FOR XPOVIOFurther company coverage: 6996.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1191","06996"],"gpt_icon":0},{"id":"2517195939","title":"Antengene Corp - Approval of Nda by Indonesia National Agency of Drug and Food Control for Xpovio","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195939?lang=en_us&edition=fundamental","pubTime":"2025-03-05 12:00","pubTimestamp":1741147235,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1574","06996","BK1191"],"gpt_icon":0},{"id":"2516689627","title":"BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516689627","media":"MT Newswires Live","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516689627?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:36","pubTimestamp":1741088212,"startTime":"0","endTime":"0","summary":"BeiGene  said Tuesday the US Food and Drug Administration approved Tevimbra, in combination with platinum-containing chemotherapy, for the first-line treatment of certain adults with unresectable or metastatic esophageal squamous cell carcinoma.The company said the approval is based on a phase 3 study where Tevimbra combination therapy showed a statistically significant improvement in overall survival.Tevimbra is also approved in the US as monotherapy for some patients with esophageal squamous cell carcinoma and in combination with chemotherapy for the first-line treatment of adults with gastric and gastroesophageal junction cancers, it added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06160","BK4139","BK1588","LU1969619763.USD","LU2328871848.SGD","LU0307460666.USD","BK1583","ONC","BK1161","BK1500","LU0588546209.SGD"],"gpt_icon":0},{"id":"2516629531","title":"BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2516629531","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516629531?lang=en_us&edition=fundamental","pubTime":"2025-03-04 18:15","pubTimestamp":1741083310,"startTime":"0","endTime":"0","summary":"BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPAMarch 4  - Hansoh Pharmaceutical Group Company Ltd 3692.HK:SECOND BIOLOGICS LICENSE APPLICATION OF XINYUE ACCEPTED BY  NMPAFurther company coverage: 3692.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","BK1191","03692"],"gpt_icon":0},{"id":"2516091626","title":"Hansoh Pharmaceutical - Second Biologics License Application of Xinyue Accepted by  Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2516091626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516091626?lang=en_us&edition=fundamental","pubTime":"2025-03-04 18:12","pubTimestamp":1741083136,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03692","BK1191","BK1589","BK1583"],"gpt_icon":0},{"id":"2516619079","title":"China Tower Corporation Limited's (HKG:788) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516619079","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516619079?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:52","pubTimestamp":1741045924,"startTime":"0","endTime":"0","summary":"China Tower (HKG:788) has had a great run on the share market with its stock up by a significant 11% over the last...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9022000-choice2-main-header/1585186701264"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/telecom/hkg-788/china-tower-shares/news/china-tower-corporation-limiteds-hkg788-stock-on-an-uptrend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BHRH8D16.HKD","00788","BK1529","IE00BHRH8C09.USD","IE00BG0RBZ43.SGD","BK1521","BK1506","BK1133","BK1583","BK1589"],"gpt_icon":0},{"id":"2516502367","title":"Greater China Stocks Close Mixed; Hong Kong Leads Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2516502367","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516502367?lang=en_us&edition=fundamental","pubTime":"2025-03-03 16:30","pubTimestamp":1740990600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Stocks in Greater China were mixed on Monday.Hong Kong's Hang Seng Index rose 0.3% to 23006.27, and China's Shanghai Composite Index slipped 0.1% to 3316.93. The Taiwan Taiex index fell 1.3% to 22756.25.Among Hang Seng constituents, Li Auto Inc. posted the largest decline, falling 4.9%, followed by shares of Semiconductor Manufacturing International Corp., which fell 4.1%. Shares of BYD Electronic  Co. Ltd. fell 3.5%.Xinyi Solar Holdings Ltd. was the biggest gainer among companies on the Hang Seng, surging 8.5%, and JD Health International Inc. surged 5.0%. Alibaba Health Information Technology Ltd. rounded out the top three movers on Monday, as shares gained 3.4%.Among large mainland China stocks, UCloud Technology Co. Ltd. A posted the largest decline, dropping 13%, followed by shares of ASR Microelectronics Co. Ltd. A, which dropped 10%. Shares of Kangxin New Materials Co. Ltd. dropped 10%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","BK1554","BK1540","600076","LU1983299162.USD","688155","LU0348767384.USD","LU0274383008.USD","BK1149","BK0214","BK0251","BK1504","BK1607","BK1571","BK1169","06618","BK1515","LU0348766576.USD","LU0456827905.SGD","BK0217","00968","BK1142","IE00BZ08YR35.GBP","00285","BK1582","LU0051755006.USD","688158","BK1502","688220","IE00BZ08YS42.EUR","BK1580","688369","BK1589","BK0245","BK1583","688776","IE00BZ08YT58.USD","BK1501","BK1163","BK1584","86618","BK1591","BK0231","BK1247","BK1526","BK1189"],"gpt_icon":1},{"id":"2516048955","title":"BeiGene's Q4'24 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2516048955","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516048955?lang=en_us&edition=fundamental","pubTime":"2025-03-03 16:20","pubTimestamp":1740990033,"startTime":"0","endTime":"0","summary":"BeiGene's  loss narrowed to $151.9 million in the fourth quarter of 2024 from $367.6 million in the year-ago period.Loss per share at the drug company narrowed to $0.11 from $0.27 in the previous year, according to a Thursday filing with the Hong Kong bourse.Total revenue surged to $1.12 billion from $630.5 million a year earlier.For 2025, full-year revenue is seen to range between $4.9 billion and $5.3 billion. It also forecasts positive GAAP operating income, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0239","06160","BK1583","LU1969619763.USD","BK1161","BK1588","688235","LU0307460666.USD","BK1500","LU0588546209.SGD"],"gpt_icon":0},{"id":"2516708635","title":"Everest Medicines Limited's (HKG:1952) biggest owners are retail investors who got richer after stock soared 3.8% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2516708635","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516708635?lang=en_us&edition=fundamental","pubTime":"2025-03-03 12:06","pubTimestamp":1740974772,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Everest Medicines by retail investors implies that the general public has more...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limiteds-hkg1952-biggest-owners-are-retail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01952","MDCO","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2516527948","title":"Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Surges 37% Yet Its Low P/S Is No Reason For Excitement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516527948","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516527948?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:36","pubTimestamp":1740962191,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. ( HKG:1877 ) shareholders would be excited to see that the share price has had a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/shanghai-junshi-biosciences-co-ltd-hkg1877-surges-37-yet-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","01877","BK1515","BK1161"],"gpt_icon":0},{"id":"2516573952","title":"Here's Why Anhui Conch Cement (HKG:914) Can Manage Its Debt Responsibly","url":"https://stock-news.laohu8.com/highlight/detail?id=2516573952","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516573952?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:09","pubTimestamp":1740960588,"startTime":"0","endTime":"0","summary":"The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2031000-choice2-main-header/1585186733208","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2031000-choice2-main-header/1585186733208"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/materials/hkg-914/anhui-conch-cement-shares/news/heres-why-anhui-conch-cement-hkg914-can-manage-its-debt-resp-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","BK1594","BK1507","EBIT","LU1328615791.USD","BK1505","00914","BK1563","BK1135"],"gpt_icon":0},{"id":"2516520520","title":"Recent 16% decline may not have gone down well with Ming Yuan Cloud Group Holdings Limited (HKG:909) insiders who've been purchasing recently","url":"https://stock-news.laohu8.com/highlight/detail?id=2516520520","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516520520?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:02","pubTimestamp":1740960123,"startTime":"0","endTime":"0","summary":"Key Insights Significant insider control over Ming Yuan Cloud Group Holdings implies vested interests in company growth...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8042000-choice1-main-header/1585186669041"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/software/hkg-909/ming-yuan-cloud-group-holdings-shares/news/recent-16-decline-may-not-have-gone-down-well-with-ming-yuan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1607","BK1518","BK1589","00909","BK1117","BK1583"],"gpt_icon":0},{"id":"2516452302","title":"Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) in Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2516452302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516452302?lang=en_us&edition=fundamental","pubTime":"2025-03-03 08:00","pubTimestamp":1740960005,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUAK75Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU2328871848.SGD","LU1969619763.USD","01801","BK1583","LU2488822045.USD","BK1589"],"gpt_icon":0},{"id":"2514342665","title":"Junshi Biosciences' 2024 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2514342665","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514342665?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:56","pubTimestamp":1740740209,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences'  attributable loss narrowed to 1.28 billion yuan in 2024 from 2.28 billion yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.Loss per share at the drug company fell to 1.30 yuan from 2.32 yuan in the previous year.Total operating income grew 30% to 1.94 billion yuan from 1.50 billion yuan a year earlier.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1515","01877","688180","BK1161","BK1583"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":1,"totalSize":61}]}}